Beta Bionics (BBNX) CCO logs small 275-share sale under Rule 10b5-1 plan

Rhea-AI Filing Summary

Beta Bionics, Inc. Chief Commercial Officer Mark Hopman reported an open-market sale of 275 shares of Common Stock at $12.31 per share. After this transaction, he directly holds 130,612 shares. The sale was executed under a pre-arranged Rule 10b5-1 Plan adopted on May 13, 2025, indicating it was scheduled in advance.

Insider Trade Summary 10b5-1

Net Seller: 275 shares ($3,385)

Net Sell 1 txn

Insider Hopman Mark

Role Chief Commercial Officer

Sold 275 shs ($3K)

Type	Security	Shares	Price	Value
Sale	Common Stock	275	$12.31	$3K

Holdings After Transaction: Common Stock — 130,612 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 275 shares Sale price: $12.31 per share Holdings after transaction: 130,612 shares

3 metrics

Shares sold 275 shares Open-market sale on June 4, 2026

Sale price $12.31 per share Average price for the 275 shares sold

Holdings after transaction 130,612 shares Direct ownership following the sale

Key Terms

Rule 10b5-1 Plan, open-market sale, Common Stock

3 terms

Rule 10b5-1 Plan regulatory

"Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 13, 2025."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hopman Mark

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CALIFORNIA 92618

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/04/2026		S(1)		275	D	$12.31	130,612	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 13, 2025.

	/s/ Stephen Feider, Attorney-in-Fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Beta Bionics (BBNX) executive Mark Hopman report in this Form 4?

Mark Hopman reported an open-market sale of 275 shares of Beta Bionics Common Stock at $12.31 per share. Following this transaction, he holds 130,612 shares directly, and the sale was made under a pre-arranged Rule 10b5-1 trading plan.

How many Beta Bionics (BBNX) shares does Mark Hopman hold after the reported sale?

After the reported sale, Mark Hopman directly holds 130,612 shares of Beta Bionics Common Stock. This context shows the 275 shares sold represent a small portion of his overall reported holdings in the company following the transaction.

At what price were the Beta Bionics (BBNX) shares sold in this insider transaction?

The reported 275 shares of Beta Bionics Common Stock were sold at an average price of $12.31 per share. This reflects an open-market transaction, as characterized in the filing, rather than a grant, option exercise, or tax-withholding event.

Was the Beta Bionics (BBNX) insider sale made under a Rule 10b5-1 plan?

Yes, the filing states the 275 shares were sold under a Rule 10b5-1 Plan adopted on May 13, 2025. Such plans are pre-arranged trading programs that schedule transactions in advance, helping separate routine portfolio management from discretionary timing decisions.

What role does Mark Hopman hold at Beta Bionics (BBNX)?

Mark Hopman is identified in the filing as the Chief Commercial Officer of Beta Bionics. The reported transaction involves his direct holdings of the company’s Common Stock and reflects an open-market sale recorded on June 4, 2026.

Does this Beta Bionics (BBNX) Form 4 include any option exercises or derivative transactions?

No, the Form 4 only reports a non-derivative transaction in Common Stock, specifically an open-market sale of 275 shares. The derivative summary is empty, indicating no option exercises, conversions, or other derivative-related transactions in this particular filing.